Placebo | SAL 50 μg | FP 500 μg | SFC 50 μg/500 μg | ICS overall | |
Patients n | 1544 | 1542 | 1552 | 1546 | |
Patients with pneumonia n | 139 | 162 | 224 | 248 | |
Probability# of pneumonia by 3 yrs % | 12.3 | 13.3 | 18.3 | 19.6 | |
Hazard ratio¶ | 1.09 | 1.53 | 1.64 | 1.52+ | |
95% CI¶ | 0.87–1.37 | 1.24–1.89 | 1.33–2.02 | 1.32–1.76+ | |
p-value¶ | 0.465 | <0.001 | <0.001 | <0.001+ |
SAL: salmeterol; FP: fluticasone propionate; SFC: SAL plus FP combination; ICS: inhaled corticosteroid (FP and SFC). #: Kaplan–Meier estimate of probability; ¶: versus placebo unless otherwise stated; +: versus non-ICS (placebo and SAL).